PT801564E - Utilizacao de nebivolol como agente anti-aterogernico - Google Patents

Utilizacao de nebivolol como agente anti-aterogernico

Info

Publication number
PT801564E
PT801564E PT95942209T PT95942209T PT801564E PT 801564 E PT801564 E PT 801564E PT 95942209 T PT95942209 T PT 95942209T PT 95942209 T PT95942209 T PT 95942209T PT 801564 E PT801564 E PT 801564E
Authority
PT
Portugal
Prior art keywords
aterogernic
nebivolol
agent
alpha
chromanmethanol
Prior art date
Application number
PT95942209T
Other languages
English (en)
Inventor
Josepha Eduarda Maria F Laysen
Didier Robert Guy G Courcelles
Anne Simone Josephine Lesage
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT801564E publication Critical patent/PT801564E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
PT95942209T 1994-12-28 1995-12-21 Utilizacao de nebivolol como agente anti-aterogernico PT801564E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28

Publications (1)

Publication Number Publication Date
PT801564E true PT801564E (pt) 2002-09-30

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95942209T PT801564E (pt) 1994-12-28 1995-12-21 Utilizacao de nebivolol como agente anti-aterogernico

Country Status (20)

Country Link
US (2) US5874461A (pt)
EP (1) EP0801564B1 (pt)
JP (1) JPH10511655A (pt)
KR (1) KR100264348B1 (pt)
CN (1) CN1167418C (pt)
AT (1) ATE214924T1 (pt)
AU (1) AU700364B2 (pt)
CA (1) CA2207333C (pt)
CZ (1) CZ287513B6 (pt)
DE (1) DE69526120T2 (pt)
DK (1) DK0801564T3 (pt)
ES (1) ES2176354T3 (pt)
FI (1) FI118884B (pt)
HU (1) HU226208B1 (pt)
NO (1) NO315687B1 (pt)
NZ (1) NZ298074A (pt)
PT (1) PT801564E (pt)
SI (1) SI0801564T1 (pt)
SK (1) SK282144B6 (pt)
WO (1) WO1996019987A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801564B1 (en) * 1994-12-28 2002-03-27 Janssen Pharmaceutica N.V. Use of nebivolol as an anti-atherogenic
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
DE60233140D1 (de) 2001-05-02 2009-09-10 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
WO2004042353A2 (en) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1741712B1 (en) 2004-07-30 2011-06-15 Torrent Pharmaceuticals Ltd amorphous form of nebivolol hydrochloride and its preparation
US20070014733A1 (en) * 2005-01-31 2007-01-18 O'donnell John P Hydroxylated nebivolol metabolites
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
CA2635280C (en) 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA038941B1 (ru) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010071800A1 (en) * 2008-12-19 2010-06-24 Schering Corporation Feed supplement for mammalian cell culture and methods of use
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
US20130065910A1 (en) * 2010-06-04 2013-03-14 Comprehensive Drug Enterprises Ltd. Oral meclizine aqueous formulations with taste flavoring agent
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
TW201615224A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 消化系統疾病用藥臨床新應用
SG10202003299PA (en) 2014-12-16 2020-05-28 Ptc Therapeutics Inc Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
AU2016369616B2 (en) 2015-12-17 2021-03-25 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
EP0801564B1 (en) * 1994-12-28 2002-03-27 Janssen Pharmaceutica N.V. Use of nebivolol as an anti-atherogenic

Also Published As

Publication number Publication date
CN1171739A (zh) 1998-01-28
SI0801564T1 (en) 2002-08-31
FI972793A (fi) 1997-06-27
NO972980L (no) 1997-06-26
CA2207333A1 (en) 1996-07-04
FI972793A0 (fi) 1997-06-27
SK282144B6 (sk) 2001-11-06
ES2176354T3 (es) 2002-12-01
AU4347796A (en) 1996-07-19
JPH10511655A (ja) 1998-11-10
SK85697A3 (en) 2000-04-10
CN1167418C (zh) 2004-09-22
US6075046A (en) 2000-06-13
NZ298074A (en) 2001-01-26
HU226208B1 (en) 2008-06-30
EP0801564B1 (en) 2002-03-27
MX9704669A (es) 1997-09-30
NO972980D0 (no) 1997-06-26
CA2207333C (en) 2006-10-17
EP0801564A1 (en) 1997-10-22
DE69526120T2 (de) 2002-11-28
HUT77927A (hu) 1998-11-30
AU700364B2 (en) 1999-01-07
CZ191997A3 (cs) 1999-01-13
CZ287513B6 (en) 2000-12-13
FI118884B (fi) 2008-04-30
DE69526120D1 (de) 2002-05-02
NO315687B1 (no) 2003-10-13
DK0801564T3 (da) 2002-07-15
US5874461A (en) 1999-02-23
KR100264348B1 (ko) 2000-08-16
WO1996019987A1 (en) 1996-07-04
ATE214924T1 (de) 2002-04-15

Similar Documents

Publication Publication Date Title
PT801564E (pt) Utilizacao de nebivolol como agente anti-aterogernico
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
HK1053989A1 (en) Fused pyrrolocarbazoles against inflammation
ATE232396T1 (de) Oxydiertes thymosin beta 4
PT998287E (pt) Utilizacao de levobupivacaina
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
CA2461117A1 (en) Botulinus toxin for treatment of body odour
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
PT1133296E (pt) Nova aplicacao terapeutica da nicergolina
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
WO1996025931A3 (en) Use of fused benzothiazoles as neuroprotectants
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
DK0820308T3 (da) Konjugat til behandling af inflammatoriske sygdomme
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür
NO984198L (no) FremgangsmÕte for behandling av aggresjon
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
NO984190L (no) FremgangsmÕte for behandling av insomnia
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії